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ception regarding vaccines and cultural concerns such as perceived
relationship of vaccine with family planning.
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Conclusion: Quinvaxem® was immunogenic and well toler-
ted when administered according to a 2-3-4 month regimen in
ietnamese infants; this study conﬁrms the excellent efﬁcacy and
afety proﬁle of Quinvaxem®.
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Background: The Global Meningococcal Initiative (GMI) is led
y international experts in meningococcal immunology, epidemi-
logy, vaccinology, and public health. The goal is to prevent
eningococcal disease (MD) through education, research, and vac-
ination.
Methods: In January 2012, the GMI met with Indian experts to
eview India’s MD burden and to explore MD prevention/control
trategies.
Results: Neisseria meningitidis is the third commonest cause
f sporadic bacterial meningitis in children <5 years, with a
igher prevalence in temperate northern versus tropical southern
egions. Actual incidence is underestimated, due to a conﬂuence
f fractured surveillance, rampant antibiotic use, and insufﬁcient
icrobiological support for diagnosis. India experiences occasional
approximately every 20 years)—but large—MD outbreaks caused
xclusively by serogroup A, with only rare reports of serogroups
and C. There have been unusual increases in the number of
D outbreaks in Delhi, Meghalaya, and Tripura since 2005. Out-
reakmanagement involvesmandatory case reporting by hospitals
n Delhi, temporarily strengthening laboratory diagnostics and
hemoprophylaxis of close contacts/high-risk groups, and limited
eactive vaccination. Currently, only meningococcal polysaccha-
ide vaccines are available in India and have successfully contained
he Meghalaya and Tripura outbreaks. However, an Indian facil-
ty is manufacturing a serogroup A conjugate vaccine for use in
ub-Saharan Africa. The GMI recommends replacement of polysac-
haride vaccines with conjugate vaccines—without necessarily
hanging current indications. Although routine immunization is
ndorsed in some settings, costs and data limitations make such
n effort not presently feasible in India. To improve surveillance,
nd thus understanding of true MD burden, the GMI recommends
1) soliciting existing reference centers to generate diagnostic data
sing RT-PCR, (2) wider use of latex agglutination tests on CSF for
onﬁrmingmeningitis, and (3) initiating carriage and seroepidemi-fectious Diseases 16S (2012) e158–e316 e305
ological studies. Until robust data are available, it will be difﬁcult
to justify prioritizing MD for routine vaccination.
Conclusion: MD burden in India is underestimated, and more
robust surveillance data are needed. Control efforts should focus
on expanding surveillance and educating physicians and regulators
of biological interventions on the importance of MD, its diagnosis,
and the need for quality data. Conjugate vaccines should be the
vaccines of choice for outbreak control and immunization of high-
risk persons.
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Factors affecting participation in a typhoid vaccine trail in
Pakistan
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Background: Participation in vaccination campaigns has
increased worldwide. However, behavioral and socio-cultural bar-
riers continue to exist in developing countries.
Methods: The study was designed to understand perceptions of
typhoid fever, gauge level of interest in a vaccine against thedisease
and experiences of participants in vaccine trial. A pre-vaccination
socio-behavioral survey was conducted on a random sample of
502 householdswith children (2-16 years) of them295 households
were accessible after the vaccination campaign. Refusal rate in our
sample was low compared to 15% in the vaccination campaign,
so to explore factors for non-participation 200 randomly selected
households were visited.
Results: Non-participants had fewer household members with
a history of typhoid fever, than participants (p <0.01); Non-
participants were less aware of anyone suffering from a serious
case of typhoid fever, than participants (p <0.01); Non-participants
were less satisﬁed with the information given them about the trial
(p <0.01). Non-participants were less satisﬁed with the trial logis-
tics (p <0.01); Non-participants were less interested in a vaccine
against typhoid fever for their children in the future (p <0.01).
Conclusion: Typhoid fever is a paediatric illness in Pakistan.
Perceived severity and vulnerability in contracting the disease and
experienceswith the illness inﬂuences decisions to take vaccine for
a disease. However, it is very imperative to consider prevailing per-
